期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地西他滨治疗骨髓增生异常综合征患者后粒细胞受抑的临床分析 被引量：11

Clinical analysis of neutrophil suppression caused by decitabine for the treatment of myelodysplastic syndromes
原文传递
导出
摘要 骨髓增生异常综合征（MDS）是起源于造血干／祖细胞，以病态造血、一系或多系血细胞减少、高风险向急性白血病转化为特征的一组异质性疾病。
作者 吴东 李晓 常春康 吴凌云 苏基滢 张曦 周立宇 宋陆茜 贺琪 肖超 张征 郭坨
机构地区 上海交通大学附属第六人民医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第2期173-175,共3页 Chinese Journal of Hematology
关键词 骨髓增生异常综合征 临床分析 地西他滨 粒细胞 造血干 祖细胞 患者 治疗 血细胞减少
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献13

  • 1Itzykson R, Fenaux P. Optimizing hypomethylating agents in myelodysplastic syndromes[J]. Curr Opin Hematol, 2012, 19 (2): 65-70. 被引量：1
  • 2Kantarjian H, Oki Y, Garcia- Manero G, et al. Results of a randomized study of 3 schedules of low- dose decitabine in higher- risk myelodysplastic syndrome and chronic myelomonocytic IeukemiaJ J]. Blood, 2007, 109( I): 52-57. 被引量：1
  • 3Steensma DP, Baer MR, SlackJL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialJ J].J Clin Oncol, 2009, 27 (23): 3842-3848. 被引量：1
  • 4无,吴德沛,阮长耿.骨髓增生异常综合征诊断与治疗专家共识[J].中华血液学杂志,2012,33(4):347-352. 被引量：75
  • 5陈瑶,黄晓军,王峰蓉,闫晨华,王昱,张圆圆,韩伟,陈欢,刘代红,刘开彦,许兰平.异基因外周血干细胞输注后24小时内发热病因分析[J].中华内科杂志,2012,51(3):179-183. 被引量：2
  • 6National Institutes of Health, National Cancer Institute. Com?mon Terminology Criteria for Adverse Events (CTCAE) Ver?sion 4.0[S]. Washington DC, United States Department of Health and Human Services, 2009. 被引量：1
  • 7Liibbert M, Suciu S, Baila L, et al. Low- dose decitabine versus best supportive care in elderly patients with intermediate- or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[J].J Clin Oncol, 2011, 29( 15): 1987-1996. 被引量：1
  • 8LeeJH, lang IH, Park I, et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome[J]. Haematologica, 2011, 96 (10): 1441-1447. 被引量：1
  • 9Kantarjian H, Issa IP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase ill randomized study[IJ. Cancer, 2006, 106 ( 8 ) : 1794-803. 被引量：1
  • 10邵秀茹,梁红,关晓军,刘晶,黄湛,王巧玲,赵娜,贡铁军,李蕊,展昭民,张伯龙,马军.地西他滨治疗中、高危骨髓增生异常综合征患者的临床研究[J].中华血液学杂志,2011,32(11):789-791. 被引量：17

二级参考文献43

  • 1石红霞,黄晓军,王峰容,韩伟,刘代红,江滨,陆道培.急性白血病患者粒细胞缺乏时发热的经验治疗[J].中国抗感染化疗杂志,2004,4(4):209-212. 被引量：6
  • 2徐泽锋,肖志坚.地汐他滨治疗骨髓增生异常综合征的研究进展[J].中华血液学杂志,2007,28(1):61-64. 被引量：4
  • 3Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase Ⅲ randomized study. Cancer, 2006,106 : 1794-1803. 被引量：1
  • 4Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a ran- domized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2007,109:52-57. 被引量：1
  • 5Cheson BD, Bennett JM, Kantarjian H, et al. Report of an inter- natinal working group to standardize response criteria for myelodys- plastic syndromes. Blood, 2000, 96:3671-3674. 被引量：1
  • 6Kantarjiau HM, O' Brieu S, Shun J, et al. Update of the deeit- abine experience in higher risk myelodysplastic syndrome and anal- ysis of prognostic factors associated with outcome. Cancer, 2007, 109:265-273. 被引量：1
  • 7Steensma DP, Baer MR, Stack JL, et al. Muhicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpa- tient treatment (ADOPT) trial. J Clin Oncol, 2009, 27:3842- 3848. 被引量：1
  • 8Kantarjian HM, O' Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007.109 : 1133-1137. 被引量：1
  • 9Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer, 2007,109:713-717. 被引量：1
  • 10de Padua Silva L, de Lima M, Kantarjian H, et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelo- dysplasticsyndrome. Bone Marrow Transplant, 2009, 43 : 839- 843. 被引量：1

共引文献132

同被引文献58

  • 1张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:1. 被引量：83
  • 2Kantarjian H, O' brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high - risk myelodysplastic syndrome: predictive prognostic models for outcome [ J]. Cancer, 2006, 106 (5) : 1090 - 1098. 被引量：1
  • 3Kantarjian HM, ThomaS XG, Dmoszynska A, et al. Multicenter, randomized, open - label, phase Ⅲ trial of decitabine versus patient choice, with physician advice, of either supportive care or low - dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [J]. J Clin Oncol, 2012, 30 (21) : 2670 - 2677. 被引量：1
  • 4Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008 : an overview [J]. Pathologica, 2010 , 102 (3): 83-87. 被引量：1
  • 5World Health Organization. WHO handbook for reporting results of cancer treatment [M]. WHO Offset Publication, 1979:15 - 16. 被引量：1
  • 6Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia:results of the MRC AML12 trial [J]. J Clin Oncol, 2010, 28 (4) : 586 - 595. 被引量：1
  • 7Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML [J]. Blood, 2011, 118 (6): 1472-1480. 被引量：1
  • 8Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia [ J ]. Ann Hematol, 2012, 91 (12): 1879-1886. 被引量：1
  • 9Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation [ J]. Leukemia, 2013, 27 (6): 1229-1235. 被引量：1
  • 10Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open - label, phase m trial of decitabine versus patient choice, with physician advice, of either supportive care or low - dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [ J ]. J Clin Oncol, 2012, 30 (21) : 2670 -2677. 被引量：1

引证文献11

二级引证文献44

中华血液学杂志
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部